Newsfeeds - Spark Newswire

2 minute read

Acorda Therapeutics Announces Agreement To Commercialize INBRIJA In Germany; Acorda Will Receive A €5M Upfront Payment, And Will Receive Additional Sales-based Milestones

Today, 5:38 AM

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it has entered into distribution and supply agreements with Esteve Pharmaceuticals GmbH (ESTEVE) to commercialize INBRIJA® 33 mg (levodopa inhalation

ACOR

1 minute read

Acorda Therapeutics Q3 EPS $(1.43) Beats $(1.56) Estimate, Sales $31.46M Beat $30.57M Estimate

By Benzinga Newsdesk

Today, 5:38 AM

Acorda Therapeutics (NASDAQ:ACOR) reported quarterly losses of $(1.43) per share which beat the analyst consensus estimate of $(1.56) by 8.33 percent. This is a 521.74 percent decrease over losses of $(0.23) per share

ACOR

21 minute read

Earnings Scheduled For November 9, 2021

By Benzinga Insights

Today, 5:38 AM

Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.

AAIC

1 minute read

Earnings

Earnings Outlook For Acorda Therapeutics

By Benzinga Insights

Today, 5:38 AM

Acorda Therapeutics (NASDAQ:ACOR) is set to give its latest quarterly earnings report on Tuesday, 2021-11-09. Here's what investors need to know before the announcement. Analysts estimate that Acorda Therapeutics will likely report an Earnings Per Share (EPS) of $-1.56

ACOR

1 minute read

12 Health Care Stocks Moving In Friday’s Pre-Market Session

By Benzinga Insights

Today, 5:38 AM

ACOR

1 minute read

Legal
News

Acorda Therapeutics US Patent & Trademark Office Abstract For Co.’s ‘Carbonate prodrugs and methods of using the same’

By Benzinga Newsdesk

Today, 5:38 AM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=11136342&OS=11136342&RS=11136342

ACOR

2 minute read

12 Health Care Stocks Moving In Friday’s Intraday Session

By Benzinga Insights

Today, 5:38 AM

ACOR

1 minute read

Earnings

Return on Capital Employed Insights for Acorda Therapeutics

By Benzinga Insights

Today, 5:38 AM

After pulling data from Benzinga Pro it seems like during Q2, Acorda Therapeutics (NASDAQ:ACOR) posted sales of $31.79 million. Earnings were up 42.24%, but Acorda Therapeutics still reported an overall loss of $16.49 million.

ACOR

1 minute read

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

Today, 5:38 AM

ACOR

6 minute read

84 Biggest Movers From Friday

By Lisa Levin

Today, 5:38 AM

Gainers

ACOR